The DOI matches its Crossref record; 244 of the 249 references it cites were found in a registry or an index.
Drug repositioning: Progress and challenges in drug discovery for various diseases
Open accessAbstract
Compared with traditional de novo drug discovery, drug repurposing has become an attractive drug discovery strategy due to its low-cost and high efficiency. Through a comprehensive analysis of the candidates that have been identified with drug repositioning potentials, it is found that although some drugs do not show obvious advantages in the original indications, they may exert more obvious effects in other diseases. In addition, some drugs have a synergistic effect to exert better clinical efficacy if used in combination. Particularly, it has been confirmed that drug repositioning has benefits and values on the current public health emergency such as the COVID-19 pandemic, which proved the great potential of drug repositioning. In this review, we systematically reviewed a series of representative drugs that have been repositioned for different diseases and illustrated successful cases in each disease. Especially, the mechanism of action for the representative drugs in new indications were explicitly explored for each disease, we hope this review can provide important insights for follow-up research.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Yet, the conventional pathway for novel drug discovery, development, and regulatory approval can span approximately 15 years, rendering it inadequate to address the immediate and growing clinical demands posed by resistant Candida infections [14, 15].”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [14]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Completing these stages can take approximately 12–17 years [14].”
From Statins as Antifungal Agents: A Review on Drug Repurposing and Nanotechnology-Driven Delivery Strategies (2025) · cites this paper as [14]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Items 201–244 of 244
Janakiram, N. B., Steele, V. E., & Rao, C. V. (2009) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-08-0140 · Cited by 39
Patil, S. P., Pacitti, M. F., Gilroy, K. S., Ruggiero, J. C., Griffin, J. D., Butera, J. J., Notarfrancesco, J. M., Tran, S., & Stoddart, J. W. (2014) · Journal of Computer-Aided Molecular Design · doi:10.1007/s10822-014-9811-6 · Cited by 38
Jin, B., Kim, H.-J., Sim, S.-A., Lee, M., & An, H. (2021) · Cells · doi:10.3390/cells10082060 · Cited by 37
Drug Repositioning for Gynecologic Tumors: A New Therapeutic Strategy for Cancer
Banno, K., Iida, M., Yanokura, M., Irie, H., Masuda, K., Kobayashi, Y., Tominaga, E., & Aoki, D. (2015) · The Scientific World JOURNAL · doi:10.1155/2015/341362 · Cited by 36
In vitro pharmacokinetics and pharmacodynamics of 1,3-bis(2-chloroethyl)-1-nitrosourea (BCNU)
Ueda-Kawamitsu, H., Lawson, T. A., & Gwilt, P. R. (2002) · Biochemical Pharmacology · doi:10.1016/s0006-2952(02)00878-x · Cited by 36
Kaplan, M. J. (2001) · PubMed · Cited by 35
Fujimiya, H., Nakashima, S., Miyata, H., & Nozawa, Y. (2009) · International Archives of Allergy and Applied Immunology · doi:10.1159/000235536 · Cited by 34
Ho, N., & Coomber, B. L. (2014) · Experimental Cell Research · doi:10.1016/j.yexcr.2014.12.006 · Cited by 31
Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer’s Disease
Monacelli, F., Cea, M., Borghi, R., Odetti, P. R., & Nencioni, A. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-160840 · Cited by 31
Studies on the antimicrobial potential of the cardiovascular drug lacidipine.
Dasgupta, A., Jeyaseeli, L., Dutta, N. K., Mazumdar, K., Karak, P., Dastidar, S. G., Motohashi, N., & Shirataki, Y. (2007) · PubMed · Cited by 31
Qiao, A., Li, J., Hu, Y., Wang, J., & Zhao, Z. (2021) · IBRO Neuroscience Reports · doi:10.1016/j.ibneur.2021.02.004 · Cited by 30
The value of drug repositioning in the current pharmaceutical market
Tobinick, E. L. (2009) · Drug News & Perspectives · doi:10.1358/dnp.2009.22.1.1303818 · Cited by 30
Leflunomide: Efficacy and safety in clinical trials for the treatment of rheumatoid arthritis
Schiff, M. H., Strand, V., Oed, C., & Loew-Friedrich, I. (2000) · Drugs of today · doi:10.1358/dot.2000.36.6.584259 · Cited by 29
Nelfinavir Is Active Against SARS-CoV-2 in Vero E6 CellsPreprint
Xu, Z., Yao, H., Shen, J., Wu, N., Xu, Y., Lu, X., Zhu, W., & Li, L. (2020) · ChemRxiv · doi:10.26434/chemrxiv.12039888.v1 · Cited by 29
Self-citationGiovanelli, A., da Silva, C. L. P. A. C., Medeiros, L., & de Vasconcellos, M. C. (2002) · Memórias do Instituto Oswaldo Cruz · doi:10.1590/s0074-02762002000500027 · Cited by 28
Acitretin modulates HaCaT cells proliferation through STAT1- and STAT3-dependent signaling
Qin, X., Chen, C., Zhang, Y., Zhang, L., Mei, Y., Long, X., Tan, R., Liang, W., & Sun, L. (2017) · Saudi Pharmaceutical Journal · doi:10.1016/j.jsps.2017.04.034 · Cited by 28
Self-citationWang, Y. (2013) · World Journal of Gastroenterology · doi:10.3748/wjg.v19.i31.5159 · Cited by 27
Garimella, T. S., Tao, X., Sims, K., Chang, Y., Rana, J., Myers, E., Wind‐Rotolo, M., Bhatnagar, R., Eley, T., LaCreta, F. P., et al. (2017) · Drugs in R&D · doi:10.1007/s40268-017-0222-8 · Cited by 25
Mercorelli, B., Luganini, A., Celegato, M., Palù, G., Gribaudo, G., & Loregian, A. (2017) · Antiviral Research · doi:10.1016/j.antiviral.2017.12.014 · Cited by 24
FDA approves galantamine for Alzheimer’s disease
Thompson, C. A. (2001) · American Journal of Health-System Pharmacy · doi:10.1093/ajhp/58.8.649a · Cited by 23
The first report of Alzheimer's disease
Drouin, E., & Drouin, G. (2017) · The Lancet Neurology · doi:10.1016/s1474-4422(17)30258-2 · Cited by 23
Lin, Y., Rahim, N. A., Zhao, J., Han, M., Yu, H. H., Wickremasinghe, H., Chen, K., Wang, J., Paterson, D. L., Zhu, Y., et al. (2019) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.02176-18 · Cited by 23
Ceccarelli, G., Alessandri, F., Oliva, A., Borrazzo, C., Dell’Isola, S., Ialungo, A. M., Rastrelli, E., Pelli, M., Raponi, G., Turriziani, O., et al. (2021) · Journal of Medical Virology · doi:10.1002/jmv.26925 · Cited by 23
Cotugnia digonopora: carbohydrate metabolism and effect of anthelmintics on immature worms
Pampori, N. A., Singh, G., & Srivastava, J. K. (1984) · Journal of Helminthology · doi:10.1017/s0022149x00028042 · Cited by 22
Finding melanoma drugs through a probabilistic knowledge graph
McCusker, J. P., Dumontier, M., Yan, R., He, S., Dordick, J. S., & McGuinness, D. L. (2017) · PeerJ Computer Science · doi:10.7717/peerj-cs.106 · Cited by 22
Samantaray, S., Correia, J., Garelnabi, M., Voelz, K., May, R. C., & Hall, R. A. (2016) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2016.04.018 · Cited by 22
Riedel, T., Demaria, O., Zava, O., Joncic, A., Gilliet, M. F., & Dyson, P. J. (2017) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00764 · Cited by 19
Organogold drug Auranofin exhibits anti-melanogenic activity in B16F10 and MNT-1 melanoma cells
Goenka, S., & Simon, S. R. (2019) · Archives of Dermatological Research · doi:10.1007/s00403-019-01974-1 · Cited by 19
Krzystanek, M., & Pałasz, A. (2020) · Pharmaceuticals · doi:10.3390/ph13100326 · Cited by 17
Tanshinone IIA induces autophagy in colon cancer cells through MEK/ERK/mTOR pathway
Qian, J., Cao, Y. L., Zhang, J., Li, L., Wu, J., Wei, G., Yu, J., & Huo, J. (2020) · Translational Cancer Research · doi:10.21037/tcr-20-1963 · Cited by 17
Therapeutic effects of thalidomide in hematologic disorders: a review
Xu, M., Hou, Y., Sheng, L., & Peng, J. (2013) · Frontiers of Medicine · doi:10.1007/s11684-013-0277-z · Cited by 15
Itraconazole perturbs colorectal cancer dormancy through SUFU-mediated WNT inhibition
Popova, S. A., & Buczacki, S. J. A. (2018) · Molecular & Cellular Oncology · doi:10.1080/23723556.2018.1494950 · Cited by 15
Yokoyama, Y., Shigeto, T., Miura, R., Kobayashi, A., Mizunuma, M., Yamauchi, A., Futagami, M., & Mizunuma, H. (2016) · Asian Pacific Journal of Cancer Prevention · doi:10.7314/apjcp.2016.17.2.775 · Cited by 14
Khan, M. B., Palaka, B. K., Sapam, T. D., Subbarao, N., & Ampasala, D. R. (2018) · Bioinformation · doi:10.6026/97320630014414 · Cited by 14
Wildcatters welcome: the need for new antimicrobial agents
Ray, A. J., & Rice, L. B. (2004) · Therapy · doi:10.2217/14750708.1.1.1 · Cited by 12
Landmark, K. H., Forsman, M., Lindberg, K. A., Ryman, T., Martmann-Moe, K., Haaverstad, S., & Wiel, S. (1995) · PubMed · Cited by 12
Capoluongo, E., Amato, F., & Castaldo, G. (2020) · Clinical Chemistry and Laboratory Medicine (CCLM) · doi:10.1515/cclm-2020-0442 · Cited by 11
Galantamine: a new treatment for Alzheimer’s disease
Wilkinson, D. G. (2001) · Expert Review of Neurotherapeutics · doi:10.1586/14737175.1.2.153 · Cited by 10
Mehnert, J. M., Wen, Y., Lee, J. H., Dudek, Ł., Pruski-Clark, L., Shih, W.-T., Chen, S., & Goydos, J. S. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2011.29.15_suppl.8557 · Cited by 10
Flupenthixol in chronic schizophrenic inpatients: a controlled comparison with haloperidol.
Ehmann, T. S., Delva, N. J., & Beninger, R. J. (1987) · PubMed · Cited by 9
Flupenthixol in Chronic Schizophrenic Inpatients
Ehmann, T. S., Delva, N. J., & Beninger, R. J. (1987) · Journal of Clinical Psychopharmacology · doi:10.1097/00004714-198706000-00011 · Cited by 8
Spontaneous Regression of Breast Cancer
Richards, C. (2009) · Archives of Internal Medicine · doi:10.1001/archinternmed.2009.89 · Cited by 7
Suthar, T. R., Gaikwad, S. T., & Suthar, A. D. (2020) · International Journal of Current Microbiology and Applied Sciences · doi:10.20546/ijcmas.2020.904.372 · Cited by 5
P3‐052: Therapeutic Links Between Anti‐Cancer Drugs (BEXAROTENE) and Alzheimer’s Disease
Pathak, K. P., & Gaire, T. (2016) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.06.1710 · Cited by 1
Research works printed but not linked: 12
- Shahnawaz Khan, 2012, 11, 369
- Rascol, 2021, 20, 1048
- Naccarati, 2012, 2, 211
- Chen, 2011, 6, 27186
- Schmidmaier, 2007, 79, 240
- Leonardi, 2018, 52, 1071
- Niu, 2002, 21, 7001
- Riedel, 2017, Drug repurposing approach identifies a synergistic drug combination of an antifungal agent and an experimental organometallic drug for melanoma treatment, Mol. Pharm., 116
- You, 2018, 28, 492
- Alsterholm, 2010, 90, 239
- Pippi, 2019, 27, 41
- Barrows, 2016, A screen of FDA-approved drugs for inhibitors of Zika virus infection, Cell Host Microbe, 259, 10.1016/j.chom.2016.07.004 · DOI
Cited by
Sorted by citations
Bai, R., Li, Y., Jian, L., Yue-hui, Y., Zhao, L., & Wei, M. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01645-2 · Cited by 297
Adachi, T., El-Hattab, A. W., Jain, R., Nogales Crespo, K. A., Quirland Lazo, C. I., Scarpa, M., Summar, M., & Wattanasirichaigoon, D. (2023) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph20064732 · Cited by 168
KG-Predict: A knowledge graph computational framework for drug repurposing
Gao, Z., Ding, P., & Xu, R. (2022) · Journal of Biomedical Informatics · doi:10.1016/j.jbi.2022.104133 · Cited by 103
Triclosan: A Small Molecule with Controversial Roles
Sinicropi, M. S., Iacopetta, D., Ceramella, J., Catalano, A. A., Mariconda, A., PELLEGRINO, M. A., Saturnino, C., Longo, P., & Aquaro, S. (2022) · Antibiotics · doi:10.3390/antibiotics11060735 · Cited by 96
A comprehensive review of computational cell cycle models in guiding cancer treatment strategies
Ma, C., & Gürkan-Çavusoglu, E. (2024) · npj Systems Biology and Applications · doi:10.1038/s41540-024-00397-7 · Cited by 63
Metadata
- Authors
- Hua, Y., Dai, X., Xu, Y., Xing, G., Liu, H., Lu, T., Chen, Y., & Zhang, Y.
- Affiliations
- China Pharmaceutical University (CN)
- Corresponding author
- Chen, Yadong
- Zhang, Yanmin
- Venue
- European Journal of Medicinal Chemistry
- Publisher
- Elsevier BV
- Published
- 2022-04
- Volume
- 234
- Pages
- 114239
- ISSN
- 0223-5234 (ISSN-L)
- PMC
- PMC8883737
- OpenAlex
- W4220885170
- Cited by
- 232
- References
- 249
- Citations by year
- 2026: 35 · 2025: 77 · 2024: 80 · 2023: 31 · 2022: 9
- FWCI
- 4.26
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Licence
- Locations
- European Journal of Medicinal Chemistry (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Natural Science Foundation of China
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Medicine › Pharmacology (medical) › Historical Medical Research and Treatments
- Keywords
- drug repurposing, drug discovery, drug synergy, combination therapy, COVID-19 pandemic, mechanism of action
- MeSH terms
- COVID-19 Drug Treatment, Humans, Drug Discovery, Drug Repositioning, Pandemics
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
